A Study of Olaratumab (LY3012207), Doxorubicin, and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma

I5B-MC-JGDR -

The purpose of this study is to evaluate the safety of ifosfamide when added to olaratumab and doxorubicin in participants with soft tissue sarcoma (STS) that is advanced or has spread to another part(s) of the body.

Trial Summary

Age Range
≥18 years
Conditions the trial is for
Sarcoma
What the trial is testing?
Doxorubicin, Ifosfamide, Mesna, Olaratumab
Could I receive a Placebo?
No
Enrollment Goal
24
Trial Dates
Oct 18, 2017 - Aug 25, 2019
How long will I be in the trial?
Your participation could last up to 16 weeks, depending on how you and your tumor respond.
Trial Phase
I

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.